Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 13, 2020

Primary Completion Date

March 30, 2024

Study Completion Date

March 30, 2024

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

C21

C21 100 mg BID (twice daily)

Trial Locations (21)

21001

Private Small Scale Enterprise Medical Center 'PULSE', Vinnytsia

61124

MNCE City Clinical Hospital, Kharkiv

65025

Odessa Regional Hospital, Odesa

79010

Lviv National Medical University, Lviv

202002

Jawaharlal Nehru Medical College - Aligarh Muslim University, Aligarh

208001

Apollo Spectra Hospitals (Apollo Speciality Hospital Pvt. Ltd.), Kanpur

380008

AMCMET Medical College and Sheth LG General Hospital, Ahmedabad

395010

Unity Hospital, Surat

400007

The Bhatia Hospital, Mumbai

400008

Grant Government Medical Collage and Sir J.J. Group of Hospitals, Mumbai

411004

Ace Hospital & Research Center, Pune

411005

Oyster & Pearl Hospitals, Pune

440019

N. K. P. Salve Institute of Medical Sciences & Research Centre and Lata Mangeshkar Hospital, Nagpur

641028

Hindusthan Hospital, Coimbatore

Unknown

Midland Healthcare and Research Centre, Lucknow

Clinical Hospital for Emergency Medical Care n.a. N.V. Solovyev, Yaroslavl

University College Hospital, London

University College London Hospitals, London

B15 2TH

University Hospital Birmingham, Birmingham

SW3 6NP

Royal Brompton Hospital, London

M23 9QZ

Medicines Evaluation Unit, Manchester

All Listed Sponsors
collaborator

Orphan Reach Ltd.

INDUSTRY

lead

Vicore Pharma AB

INDUSTRY

NCT04533022 - Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF | Biotech Hunter | Biotech Hunter